How Many Allergy Shots Do You Need? Total Injection Count Explained

The total number of allergy shots needed for a full course ranges from approximately 96 to 380 injections across 3-5 years. This wide range reflects variation in build-up protocol (conventional vs. cluster vs. rush), maintenance interval (monthly vs. biweekly), treatment duration (3 vs. 5 years), and allergen count (1 vs. 2 injections per visit). For a typical patient on conventional once-weekly build-up followed by monthly maintenance for 3 years with a single injection per visit, the total is approximately 99-108 injections. For a polysensitized patient on biweekly maintenance for 5 years with two injections per visit, the total approaches 380.

During the conventional build-up phase, most patients receive approximately 24-30 injections for a once-weekly schedule or 48-60 injections for a twice-weekly schedule. Cluster protocols deliver 30-60 build-up injections but compress them into 4-8 weeks rather than 3-6 months. Rush protocols deliver 8-24 injections over just 1-3 days. The specific injection count in build-up depends on how many concentration steps your allergist's protocol uses and how frequently you come in. Polysensitized patients receiving two injections per visit will have double the raw injection count during build-up, even though they have the same number of clinic visits as monosensitized patients.

During maintenance, allergy shots are given every 2-4 weeks, generating approximately 13 injections per year at monthly intervals or approximately 26 injections per year at biweekly intervals. Most adult patients on monthly maintenance receive exactly 13 injections in a calendar year (52 weeks divided by 4 weeks between injections = 13). Patients on biweekly maintenance receive 26. If you receive 2 injections per visit due to multiple allergen groups, these counts double. Over the 3-5 year maintenance phase, the total maintenance injection count ranges from approximately 39 (3 years, monthly, one shot per visit) to 130 (5 years, biweekly, one shot per visit).

Allergy shots begin producing measurable immune changes well before the full course is complete. IgG4 blocking antibodies — the molecular mediators of allergen tolerance — begin rising within 4-8 weeks of treatment initiation and reach clinically meaningful levels by approximately injection 20-30, which typically corresponds to mid-build-up phase per Shamji and Durham (JACI 2017). Most patients notice the first symptoms of clinical improvement during months 3-6, which aligns with completing the build-up phase and beginning maintenance. Full disease modification — the durable immune retraining that outlasts treatment — requires completing the full 3-5 year course, not just the first 20-30 injections.

Patients with multiple allergen sensitivities may receive 2 injections per clinic visit — one in each arm — if their allergen extracts cannot be safely mixed in a single vial. When this happens, the raw injection count doubles, though the number of clinic visits does not change. A polysensitized patient on monthly maintenance with 2 injections per visit receives 26 injections per year in maintenance (vs. 13 for a monosensitized patient), and may accumulate 380+ total injections over a 5-year course with biweekly maintenance. Some practices consolidate allergens into a single mixed vial, reducing the per-visit injection count to one — your allergist determines what is safe to combine based on extract compatibility.

The total injection count can be reduced in a few ways. First, choosing a shorter treatment duration: a 3-year course involves significantly fewer maintenance injections than 5 years, though 5 years produces better long-term disease modification (Durham, NEJM 1999). Second, opting for monthly rather than biweekly maintenance when your allergist determines both are appropriate for your symptom control. Third, allergen consolidation into mixed vials, when safe, reduces per-visit injection count. Fourth, for established maintenance patients (2+ years), some allergists extend intervals to 5-6 weeks, reducing the annual injection count. None of these reductions significantly compromise outcomes when implemented appropriately.